Coherus Oncology, Inc. (CHRS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Coherus Oncology, Inc.
Address
333 Twin Dolphin Drive
Redwood City, CA 94065
United States of America (the)
Phone
650 649 3530
Website
Sector
Healthcare
Industry
Biotechnology
Employees
228
First IPO Date
November 06, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Dennis Lanfear | Chairman, President & Chief Executive Officer | 1.91M | 1955 |
| Bryan J. McMichael | Chief Financial Officer | 788,885 | 1979 |
| Sameer Goregaoker | Chief Commercial Officer | 854,058 | N/A |
| Rosh Dias MRCP | Chief Medical Officer | 0 | 1968 |
| Arvind Sood | Chief Strategy & Corporate Affairs Officer | 0 | N/A |
| Rebecca Sunshine | Chief Human Resources Officer | 0 | 1963 |
| Michael Chen | Senior Vice President of Commercial Analytics & Trade | 0 | N/A |
| Carrie Graham | Vice President of Investor Relations & Advocacy | 0 | N/A |
| Theresa Lavallee | Chief Development Officer & Chairman of Scientific Advisory Board | 0 | 1966 |
| Andy Rittenberg | Chief Legal Officer | 0 | N/A |
Description
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
